scholarly journals EVALUATION OF THE AUSTRALIAN CAPITAL TERRITORY 2019 PILOT PROGRAM FOR PHARMACIST ADMINISTRATION OF NATIONAL IMMUNISATION PROGRAM INFLUENZA VACCINE TO PEOPLE AGED 65 YEARS AND OVER

2020 ◽  
Vol 50 (S1) ◽  
pp. 9-9
Keyword(s):  
Influenza Vaccine ◽  
Pilot Program ◽  
Australian Capital Territory ◽  
Australian Capital ◽  
National Immunisation ◽  
National Immunisation Program

scholarly journals Influenza hospitalizations in Australian children

2017 ◽  
Vol 145 (7) ◽  
pp. 1451-1460 ◽  
Author(s):  
J. LI-KIM-MOY ◽  
J. K. YIN ◽  
C. C. BLYTH ◽  
A. KESSON ◽  
R. BOOY ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Influenza Vaccination ◽  
Influenza A ◽  
Immunization Coverage ◽  
Population Level ◽  
Vaccine Safety ◽  
Vaccine Uptake ◽  
Healthy Children ◽  
National Immunisation ◽  
National Immunisation Program

SUMMARYAustralia's National Immunisation Program (NIP) provides free influenza vaccination for children at high risk of severe influenza; a pilot-funded programme for vaccine in all children aged 6 months to <5 years in one of eight states, has seen poor vaccine impact, related to recent vaccine safety concerns. This retrospective review examined influenza hospitalizations in children aged <16 years from three seasons (2011–2013) at two paediatric hospitals on opposite sides of the country. Comparisons of this cohort were made with state-based data on influenza-coded hospitalizations and national immunization register data on population-level immunization coverage. Of 740 hospitalizations, the majority were aged <5 years (476/740, 64%), and a substantial proportion (57%) involved healthy children, not currently funded for influenza vaccine. Intensive care unit admission occurred in 8·5%, and 1·5% of all children developed encephalitis. Use of antiviral therapy was uncommon (20·5%) and decreasing. Of those hospitalized, only 5·0% of at-risk children, who are currently eligible for free vaccine, and 0·7% of healthy children were vaccinated prior to hospitalization. This was consistent with low population-wide estimates of influenza vaccine uptake. It highlights the need to examine alternative strategies, such as universally funded paediatric influenza vaccination, to address disease burden in Australian children.

scholarly journals Immunisation Coverage Annual Report 2018

2021 ◽  
Vol 45 ◽  
Author(s):  
Brynley Hull ◽  
Alexandra Hendry ◽  
Aditi Dey ◽  
Peter McIntyre ◽  
Kristine Macartney ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Torres Strait Islander ◽  
Vaccine Coverage ◽  
Rotavirus Vaccine ◽  
Immunisation Coverage ◽  
National Immunisation ◽  
Vaccine Schedule ◽  
National Immunisation Program ◽  
Indigenous Children ◽  
Torres Strait

Australian Immunisation Register data have been analysed for children aged < 5 years, focusing on changes in coverage at key milestone ages (12, 24 and 60 months) between 2017 and 2018, while also documenting longer term trends. Fully vaccinated coverage increased at the 12- and 60-months milestones to 93.9% and 94.0%, respectively, but, in the context of additional antigens required, decreased to 90.1% at 24 months. Following the move to a two-dose rotavirus vaccine schedule across Australia from mid-2017, rotavirus vaccine coverage increased from 86.8% to 90.9%. In 2018, most jurisdictions funded influenza vaccine for non-Indigenous children aged 6 months to < 5 years; the National Immunisation Program has funded influenza vaccine for Aboriginal and Torres Strait Islander children and medically at-risk children since 2015 and 2010, respectively. Recorded influenza vaccine coverage in Aboriginal and Torres Strait Islander children doubled from 14.9% to 31.4%, and increased fivefold in non-Indigenous children from 5.0% to 25.9% in 2018. The timeliness of fully vaccinated coverage was also examined at earlier milestones (3 months after due date of last scheduled vaccine) of 9, 15, 21 and 51 months, by area of residence. For all children, coverage among those living in the least advantaged residential area quintile was 3–4% lower than that for those in the most advantaged quintile at the 9-, 15- and 21-month milestones. Importantly, although Aboriginal and Torres Strait Islander children had lower coverage for the second dose of measles-mumps-rubella vaccine at 24 months (91.8% versus 93.1% for non-Indigenous), coverage increased to 98.5% at 60 months; coverage was also high in non-Indigenous children at 96.2%, above the 95% target critical to measles control. These data demonstrate continuing improvements in immunisation coverage and suggest potential new coverage targets for earlier protection in the first two years of life.

scholarly journals Immunisation Coverage Annual Report 2018

2021 ◽  
Vol 45 ◽  
Author(s):  
Brynley Hull ◽  
Alexandra Hendry ◽  
Aditi Dey ◽  
Peter McIntyre ◽  
Kristine Macartney ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Torres Strait Islander ◽  
Vaccine Coverage ◽  
Rotavirus Vaccine ◽  
Immunisation Coverage ◽  
National Immunisation ◽  
Vaccine Schedule ◽  
National Immunisation Program ◽  
Indigenous Children ◽  
Torres Strait

Australian Immunisation Register data have been analysed for children aged < 5 years, focusing on changes in coverage at key milestone ages (12, 24 and 60 months) between 2017 and 2018, while also documenting longer term trends. Fully vaccinated coverage increased at the 12- and 60-months milestones to 93.9% and 94.0%, respectively, but, in the context of additional antigens required, decreased to 90.1% at 24 months. Following the move to a two-dose rotavirus vaccine schedule across Australia from mid-2017, rotavirus vaccine coverage increased from 86.8% to 90.9%. In 2018, most jurisdictions funded influenza vaccine for non-Indigenous children aged 6 months to < 5 years; the National Immunisation Program has funded influenza vaccine for Aboriginal and Torres Strait Islander children and medically at-risk children since 2015 and 2010, respectively. Recorded influenza vaccine coverage in Aboriginal and Torres Strait Islander children doubled from 14.9% to 31.4%, and increased fivefold in non-Indigenous children from 5.0% to 25.9% in 2018. The timeliness of fully vaccinated coverage was also examined at earlier milestones (3 months after due date of last scheduled vaccine) of 9, 15, 21 and 51 months, by area of residence. For all children, coverage among those living in the least advantaged residential area quintile was 3–4% lower than that for those in the most advantaged quintile at the 9-, 15- and 21-month milestones. Importantly, although Aboriginal and Torres Strait Islander children had lower coverage for the second dose of measles-mumps-rubella vaccine at 24 months (91.8% versus 93.1% for non-Indigenous), coverage increased to 98.5% at 60 months; coverage was also high in non-Indigenous children at 96.2%, above the 95% target critical to measles control. These data demonstrate continuing improvements in immunisation coverage and suggest potential new coverage targets for earlier protection in the first two years of life.

Surveillance of adverse events following immunisation in Australia annual report, 2017

2019 ◽  
Vol 43 ◽  
Author(s):  
Aditi Dey ◽  
Han Wang ◽  
Helen Quinn ◽  
Rona Hiam ◽  
Nicholas Wood ◽  
...  
Keyword(s):  
Adverse Events ◽  
Annual Report ◽  
Injection Site Reaction ◽  
Reporting Rate ◽  
Vaccination Programs ◽  
National Immunisation ◽  
National Immunisation Program ◽  
Conjugate Vaccination ◽  
Reporting Rates ◽  
To Receive

This report summarises Australian passive surveillance data for adverse events following immunisation (AEFI) for 2017 reported to the Therapeutic Goods Administration and describes reporting trends over the 18-year period 1 January 2000 to 31 December 2017. There were 3,878 AEFI records for vaccines administered in 2017; an annual AEFI reporting rate of 15.8 per 100,000 population. There was a 12% increase in the overall AEFI reporting rate in 2017 compared with 2016. This increase in reported adverse events in 2017 compared to the previous year was likely due to the introduction of the zoster vaccine (Zostavax®) provided free for people aged 70–79 years under the National Immunisation Program (NIP) and also the state- and territory-based meningococcal ACWY conjugate vaccination programs. AEFI reporting rates for most other individual vaccines in 2017 were similar to 2016. The most commonly reported reactions were injection site reaction (34%), pyrexia (17%), rash (15%), vomiting (8%) and pain (7%). The majority of AEFI reports (88%) described non-serious events. Two deaths were reported that were determined to have a causal relationship with vaccination; they occurred in immunocompromised people contraindicated to receive the vaccines.

A geoid for the Australian capital territory

1997 ◽  
Vol 42 (1) ◽  
pp. 25-32
Author(s):  
Kevin A. Freund ◽  
Jim Steed ◽  
A.H.W. Kearsley
Keyword(s):  
Australian Capital Territory ◽  
Australian Capital
Sign in / Sign up

Export Citation Format

Share Document